FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567332472> ?p ?o ?g. }

• W1567332472 endingPage "179" @default.
• W1567332472 startingPage "179" @default.
• W1567332472 abstract "A 67-year-old man with chronic lymphocytic leukemia (CLL) and deletion of chromosome 17p presented to clinic for evaluation of leukocytosis (total white blood cell count 149,000/mm3, absolute lymphocyte count 144,000/mm3) associated with fatigue, drenching night sweats, and recurrent viral infections. He had been treated previously with a combination of rituximab, cyclophosphamide, vincristine, and prednisone as well as rituximab and bendamustine (B-R), with the most recent therapy 3 years prior to his clinic visit. He had previously declined referral for hematopoietic stem cell evaluation. He was started on ibrutinib 420 mg PO daily in combination with allopurinol 300 mg PO daily for prophylaxis against tumor lysis syndrome. Two weeks after beginning therapy, he developed a painless, non-pruritic, rash that began on his wrists and then spread to his entire body (Image 1). The rash was characterized by a diffuse distribution of bright red edematous papules, ranging from 0.5 to 1 cm in diameter, with sparing of his palms and soles. He was evaluated in the Emergency Department and both allopurinol and ibrutinib were held. His absolute eosinophil count at the time was within the normal range (100/mm3). Within several days his rash had completely resolved, and given consideration for allopurinol as the etiology of his rash, he was restarted on dose-reduced ibrutinib (140 mg PO daily) without allopurinol. After a single dose, he developed recrudescence of his full-body rash and ibrutinib was once again discontinued. The rash again resolved within several days of discontinuing ibrutinib. Ibrutinib (Imbruvica, Pharmacyclics/Janssen Biotech), an oral Bruton's tyrosine kinase inhibitor, was approved in February 2014 by the Federal Drug Administration for the treatment of CLL patients who have received at least one prior therapy. Ibrutinib is generally very well-tolerated, with few Grade 3 or higher adverse events 1-3. In published studies, rash occurs at a frequency of 15–27%, although no identifying characteristics have been reported. In this case, clinical features distinguishing the rash from a classic allopurinol-mediated rash included its presentation with edematous papules (versus the morbilliform rash commonly associated with allopurinol) and its peripheral-to-central pattern of spread. Painless, non-pruritic edematous papules on the trunk of a patient who developed an ibrutinib-related rash. Lesions began on the wrists and arms and subsequently generalized to the entire body." @default.
• W1567332472 created "2016-06-24" @default.
• W1567332472 creator A5014821670 @default.
• W1567332472 creator A5018602876 @default.
• W1567332472 creator A5066973570 @default.
• W1567332472 creator A5081155388 @default.
• W1567332472 creator A5085672843 @default.
• W1567332472 date "2014-06-20" @default.
• W1567332472 modified "2023-10-16" @default.
• W1567332472 title "Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia" @default.
• W1567332472 cites W2071549499 @default.
• W1567332472 cites W2140395974 @default.
• W1567332472 cites W2154066874 @default.
• W1567332472 doi "https://doi.org/10.1002/ajh.23775" @default.
• W1567332472 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4548957" @default.
• W1567332472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24890909" @default.
• W1567332472 hasPublicationYear "2014" @default.
• W1567332472 type Work @default.
• W1567332472 sameAs 1567332472 @default.
• W1567332472 citedByCount "18" @default.
• W1567332472 countsByYear W15673324722015 @default.
• W1567332472 countsByYear W15673324722016 @default.
• W1567332472 countsByYear W15673324722017 @default.
• W1567332472 countsByYear W15673324722018 @default.
• W1567332472 countsByYear W15673324722019 @default.
• W1567332472 countsByYear W15673324722020 @default.
• W1567332472 countsByYear W15673324722021 @default.
• W1567332472 countsByYear W15673324722022 @default.
• W1567332472 countsByYear W15673324722023 @default.
• W1567332472 crossrefType "journal-article" @default.
• W1567332472 hasAuthorship W1567332472A5014821670 @default.
• W1567332472 hasAuthorship W1567332472A5018602876 @default.
• W1567332472 hasAuthorship W1567332472A5066973570 @default.
• W1567332472 hasAuthorship W1567332472A5081155388 @default.
• W1567332472 hasAuthorship W1567332472A5085672843 @default.
• W1567332472 hasBestOaLocation W15673324721 @default.
• W1567332472 hasConcept C126322002 @default.
• W1567332472 hasConcept C16005928 @default.
• W1567332472 hasConcept C2776694085 @default.
• W1567332472 hasConcept C2776755627 @default.
• W1567332472 hasConcept C2777063308 @default.
• W1567332472 hasConcept C2777938653 @default.
• W1567332472 hasConcept C2778461978 @default.
• W1567332472 hasConcept C2778570526 @default.
• W1567332472 hasConcept C2778923028 @default.
• W1567332472 hasConcept C2779338263 @default.
• W1567332472 hasConcept C2779429289 @default.
• W1567332472 hasConcept C2779878957 @default.
• W1567332472 hasConcept C2780653079 @default.
• W1567332472 hasConcept C2781442060 @default.
• W1567332472 hasConcept C71924100 @default.
• W1567332472 hasConcept C74133956 @default.
• W1567332472 hasConcept C90924648 @default.
• W1567332472 hasConceptScore W1567332472C126322002 @default.
• W1567332472 hasConceptScore W1567332472C16005928 @default.
• W1567332472 hasConceptScore W1567332472C2776694085 @default.
• W1567332472 hasConceptScore W1567332472C2776755627 @default.
• W1567332472 hasConceptScore W1567332472C2777063308 @default.
• W1567332472 hasConceptScore W1567332472C2777938653 @default.
• W1567332472 hasConceptScore W1567332472C2778461978 @default.
• W1567332472 hasConceptScore W1567332472C2778570526 @default.
• W1567332472 hasConceptScore W1567332472C2778923028 @default.
• W1567332472 hasConceptScore W1567332472C2779338263 @default.
• W1567332472 hasConceptScore W1567332472C2779429289 @default.
• W1567332472 hasConceptScore W1567332472C2779878957 @default.
• W1567332472 hasConceptScore W1567332472C2780653079 @default.
• W1567332472 hasConceptScore W1567332472C2781442060 @default.
• W1567332472 hasConceptScore W1567332472C71924100 @default.
• W1567332472 hasConceptScore W1567332472C74133956 @default.
• W1567332472 hasConceptScore W1567332472C90924648 @default.
• W1567332472 hasIssue "2" @default.
• W1567332472 hasLocation W15673324721 @default.
• W1567332472 hasLocation W15673324722 @default.
• W1567332472 hasLocation W15673324723 @default.
• W1567332472 hasLocation W15673324724 @default.
• W1567332472 hasLocation W15673324725 @default.
• W1567332472 hasOpenAccess W1567332472 @default.
• W1567332472 hasPrimaryLocation W15673324721 @default.
• W1567332472 hasRelatedWork W1498432575 @default.
• W1567332472 hasRelatedWork W1515202398 @default.
• W1567332472 hasRelatedWork W1972939890 @default.
• W1567332472 hasRelatedWork W2081126084 @default.
• W1567332472 hasRelatedWork W2165669261 @default.
• W1567332472 hasRelatedWork W2593690797 @default.
• W1567332472 hasRelatedWork W2599151900 @default.
• W1567332472 hasRelatedWork W2963940374 @default.
• W1567332472 hasRelatedWork W3048067521 @default.
• W1567332472 hasRelatedWork W3191871611 @default.
• W1567332472 hasVolume "90" @default.
• W1567332472 isParatext "false" @default.
• W1567332472 isRetracted "false" @default.
• W1567332472 magId "1567332472" @default.
• W1567332472 workType "article" @default.